Tissue transglutaminase autoantibodies (tTGAs) represent the fi rst evidence of celiac disease (CD) development. Associations of HLA-DR3-DQA1*05:01-DQB1*02:01 (i.e., DR3-DQ2) and, to a lesser extent, DR4-DQA1*03:01-DQB1*03:02 (i.e., DR4-DQ8) with the risk of CD differ by country, consistent with additional genetic heterogeneity that further refi nes risk. Therefore, we examined human leukocyte antigen (HLA) factors other than DR3-DQ2 for their contribution to developing tTGAs.
INTRODUCTION
Celiac disease (CD) is a common small bowel disorder with autoimmune features, typically preceded by the development of autoantibodies against tissue transglutaminase autoantibodies (tTGAs) ( 1 ) . CD has strong genetic associations linked to the human leukocyte antigen (HLA) genes coding for the major histocompatibility complex class II complex on chromosome 6, and a similar pattern of genetic association has recently been found in relation to the development of tTGAs.
Individuals developing CD are mainly carriers of HLA-DR3 in linkage disequilibrium (LD) with the DQA1*05:01-DQB1*02:01 (abbreviated as DR3-DQ2) haplotype, and a minority carry HLA-DR4-DQA1*03:01-DQB1*03:02 (abbreviated as DR4-DQ8) ( 2 ) . Th e DR3-DQ2/DR3-DQ2 genotype is known as having the highest risk for CD, with these homozygous individuals at two-fold risk compared with those individuals with one copy of DR3-DQ2, implying an HLA gene-dose eff ect (3) (4) (5) . Th is genetic association was also recently published in relation to tTGAs, with a gene-dose eff ect of DR3-DQ2 on the risk of developing tTGAs in young children ( 6 ) .
Both the DR3-DQ2 and DR4-DQ8 haplotypes are common in the Caucasian population ( 7 ) , suggesting that, apart from environmental factors, additional genes contribute to CD susceptibility ( 8 ) . Recent genome-wide association studies (GWAS) have identifi ed risk variants (single-nucleotide polymorphisms (SNPs)) in 40 non-HLA loci that contribute to additional risk, although of minor eff ect, for CD ( 9 ) . Others have fi ne-mapped the HLA complex for nearby risk alleles and have identifi ed four putatively independent risk loci for CD ( 10 ) .
In the ongoing multicenter Th e Environmental Determinants of Diabetes in the Young (TEDDY) study, the risk association for CD varied among the DR3-DQ2/DR3-DQ2 carriers across our study population, indicating that HLA alleles other than DR3-DQ2 might aff ect the risk ( 6 ) . Given the similar genetic association between both tTGA autoimmunity and overt disease with the DR3-DQ2 locus, we examined whether other HLA variants are associated with autoimmunity development, as has been done for CD in the past, with various levels of association previously reported ( 11, 12 ) . To dissect this diff erence, we performed non-HLA-DR-DQ analysis on those children who developed tTGAs and in HLA-DR-DQ-matched controls.
METHODS

TEDDY cohort
TEDDY consortium of six clinical centers in Germany, Finland, Sweden, and the United States screened 424,788 newborns for HLA-DR-DQ genotypes associated with T1D and CD between 2004 and 2010 ( 13 ) . Certain HLA genotypes were used as an eligibility criterion to select subjects with an increased risk for developing T1D ( Table 1 ) . Of the 21,589 screened newborns with an increased genetic risk, 8,676 were enrolled in prospective followup ( Table 2 ). TEDDY was approved by local Ethical Institutional Review Boards and is monitored by an External Evaluation Committee formed by the National Institutes of Health.
Screening for CD
Annual screening for CD autoimmunity with tTGAs starts at 2 years of age in TEDDY, as previously described ( 6 ) . All tTGA-positive children at 2 and 3 years of age are retested aft er 3 months, whereas children initially positive at 4 years or older are retested aft er 6 months. For children who tested positive at 2 years of age, we retrospectively analyzed their banked serum samples (collected over multiple clinic visits earlier) for tTGA to estimate the fi rst time point of antibody positivity (seroconversion). Children who tested persistently positive for tTGA in two consecutive samples are defi ned as having CD autoimmunity (CDA). Guardians to children with a positive test result of tTGA were informed and, if confi rmed on the next sample, were recommended to seek consultation of a pediatric gastroenterologist at their local hospital for further evaluation of CD.
tTGA measurements tTGAs were detected by standardized radiobinding assay using recombinant 35 S-labeled tTG measured in two laboratories, as previously described ( 14 ) . Serum samples from the US participants were screened for IgA-tTG at the Barbara Davis Center for Childhood Diabetes at the University of Colorado in Denver (cutoff for normal <0.05 relative units). Serum samples from European participants were assayed at the University of Bristol in Bristol for both IgA-tTG and IgG-tTG (cutoff for normal <1.3 relative units). All samples with IgA-tTG levels ≥0.01 units assessed in Denver were sent to Bristol for reanalysis, which was used as the reference laboratory ( 15 ) .
Nested case-control design and genotyping
High-resolution sequence-based typing of the HLA-B, -DRB3, -DRB4, -DPA1, and -DPB1 genes was performed in 250 children (cases) who developed persistent positive tTGAs (i.e., CDA) and 250 control children matched on country, sex, and the presence of a DR3-DQ2 haplotype. Genomic DNA was typed based on Roche 454 sequencing. Aft er excluding subjects with missing genotype data, 248 matched pairs remained for analysis ( Table 3 ) .
SNP genotyping
SNPs were genotyped by the Center for Public Health Genomics at University of Virginia, using the Illumina ImmunoChip SNP microarray (Illumina Inc., San Diego, CA) of ~196,000 SNPs selected from 186 regions associated with 12 autoimmune diseases. Individuals with low call rate (>5% SNPs missing), or discordance with reported sex and prior genotyping, were not considered in the analysis. In addition, SNP markers with low call rates (<95%) or with allele distributions strongly deviating from Hardy-Weinberg equilibrium ( P <10 −6 ) were discarded (except for chromosome 6 due to HLA eligibility requirements). Th is resulted in a total of 7,023 subjects with genotype data on 176,586 SNPs.
Imputation
In addition to the 496 subjects in the nested case-control data set, SNP data on individuals from the remainder of the TEDDY cohort were used for the imputation of HLA alleles using the method developed by Jia et al. ( 16 ) Reference HLA data from the Type 1 Diabetes Genetics Consortium were used to impute values for the TEDDY cohort. We chose to limit the cohort to the more common HLA screening genotypes ( Table 1 , categories A-D) in order to make interpretation of the analysis as generalizable as possible. In addition to the nested case-control groups, this imputation provided HLA information on 4,514 unrelated subjects (median follow-up age=4.2 years, interquartile range=2.9 years) in addition to the nested case-control groups, of which 432 had developed CDA at the time of the data freeze (31 August 2013).
Statistical analysis
For the HLA-B, -DRB3, -DRB4, -DPA1, and -DPB1 genes, only alleles with frequency ≥5% were considered ( Table 4 ) . Association tests used conditional logistic regression models for nested case-control analyses, and Cox proportional hazard models for the replication data set from the remainder of the cohort with covariates as indicated in the results section below. Analyses accounted for the known covariates of HLA category, sex, and country.
RESULTS
We fi rst analyzed the 496 subjects in the nested case-control data set, which includes 248 individuals with CDA. Of the alleles tested, only the DPB1*04:01 allele was signifi cantly associated with CDA risk (odds ratio=0.71, 95% confi dence interval (CI)=0.53-0.96, P =0.025) in a conditional logistic regression model. Th e model included the number of HLA-DR3-DQ2 copies as the only additional covariate, as the controls were already selected to match on sex and country.
Having imputed the HLA-DPB1*04:01 in a majority of the TEDDY cohort using ImmunoChip SNP genotypes, we were able to compare the results from imputation with the directly genotyped HLA. Th e concordance between the imputed and genotyped HLA allele was high, with only 11/481 (2.3%) results being discordant for HLA-DPB1*04:01.
Although the imputation method was validated using Type 1 Diabetes Genetics Consortium and 1958 British Birth Cohort subjects of European ancestry, we explored whether the restriction to a similar group in TEDDY would improve concordance. Th ere was no evidence of improved concordance when restricting to non-Hispanic White subjects from the US (self-reported ethnicity, where available). Of the 11 discordant results, only 1 observation was dropped when limiting by ethnicity. Yet, when using the ethnic information, an additional 15 concordant results were included. Hadley et al.
Th erefore, the imputation method appeared to work eff ectively in individuals of both European and non-European ancestry.
Regardless of the high imputation concordance in diff erent ethnic groups, to avoid the possibility of association owing to population stratifi cation, we limited our analysis to the imputed results in the 4,514 subjects with a self-reported Caucasian ancestry. Ethnicity information was only available for the subjects at US centers, which makes up 43% of the TEDDY population. In those subjects, 73% self-reported to be Caucasian ( Table 2 ). In the few instances in which self-reported ethnicity was available at European centers, non-Caucasian subjects were removed from the analysis. For the majority of subjects at the European centers, we have previously reported homogeneity in a principal components analysis within each country, as well as strong similarity between the European countries and the US Caucasians ( 17 ) .
Proportional hazards modeling was performed to test for association with time to seroconversion of tTGAs in CDA children in those unrelated TEDDY subjects who were not part of the nested case-control group. Using a Cox proportional hazards model, with sex, country, and HLA genotype category as covariates, we tested for the association between HLA-DPB1*04:01 and time to tTGA development ( Table 3 ). To account for any potential diff erences between DR4-DQ8/DR4-DQ8 and DR4-DQ8/DR8-DQ4, we adjusted for HLA category, rather than the number of copies of DR3-DQ2. Th e association between HLA-DPB1*04:01 and time to seroconversion was signifi cantly replicated in the larger cohort (hazard ratio=0.84, 95% CI=0.73-0.96, P =0.013; Table 5 ).
Th e HLA-DPB1*04:01 allele was common among the four HLA-DR-DQ risk categories used in the study eligibility criteria ( Table 6 ). We observed that the HLA categories correspond to the familiar pattern of DR3 conferring risk: a doubling of risk between category A (DR4-DQ8/DR3-DQ2) to category D (DR3-DQ2/DR3-DQ2) and a decrease in risk with no copies of DR3-DQ2 (categories B and C). In addition, as expected, the eff ect of female sex is associated with a signifi cant increase in the risk of CDA. Despite accounting for the above covariates, and including a new HLA marker for risk to the model, there is also a signifi cant diff erence in risk between countries: Swedish and Finnish subjects both having an increased risk of CDA compared with subjects in the USA.
DISCUSSION
In this study, we analyzed genetic associations with the phenotype of persistent tTGAs, which we termed CDA. Th is represents an early stage of CD, which generally precedes the clinical diagnosis by months to years, likely owing to the rarity of general pediatric antibody screening, as well as obvious logistical diffi culties associated with endoscopic biopsy. It is also true that some children Reference country is the USA, reference sex is male, and reference HLA category is A (see Table 1 ). 
PEDIATRICS
Celiac Disease and Extended HLA Genotypes
Th e HLA-DPB1*04:01 allele may be in LD with the 8.1 ancestral multi-gene haplotype, known to be associated with various autoimmune diseases ( 27 ) : HLA A*0101: Cw*0701: B*0801: DRB1*0301: DQA1*0501: DQB1*0201. Given that DR3-DQ2 was included as a covariate in the modeling, it is likely that the observed association of HLA-DPB1*04:01 with the risk of CDA development is independent of the 8.1 ancestral haplotype in this population. Using the TEDDY imputed data, the LD between DR3-DQ2 from study screening and imputed HLA-DPB1*04:01 in 4514 European ancestry subjects was found to be r 2 =0.01, D'=0.14. Th e TEDDY study is enriched for children with CDA and CD compared with other birth cohorts, owing to the screening based on increased risk HLA haplotypes. Although this off ers insights into eff ects that may otherwise be diffi cult to observe in the general population, one drawback is a lack of Hardy-Weinberg equilibrium in the HLA screening polymorphisms (and other genetic variants in LD with them). Departure from HardyWeinberg equilibrium violates the assumptions of many useful statistical techniques, such as haplotype imputation from genotypes. Another statistical technique that requires Hardy-Weinberg equilibrium is the calculation of LD between DR3-DQ2 and DPB1*04:01. Because of these limitations, and as the HLA region has particularly high and complex LD, future studies may wish to investigate the haplotype eff ect of DPB1*04:01 and its LD with the 8.1 ancestral haplotype, although the LD appears to be low in our data.
In summary, we believe that this is the fi rst publication of HLA allele associations with the development of CDA beyond the DR3-DQ2 haplotype. Because CDA appears earlier in disease development than clinical CD, HLA-DPB1*04:01 typing may increase the ability to defi ne children at risk for CD, allowing for better prospective prediction of CD risk in birth cohorts. For prospective studies, such as TEDDY, better defi nition of disease risk should enable improved focus on environmental risk factors that may act as triggers for CDA in children at genetic risk. Further, these fi ndings may allow improvement of population-based strategies for tTGA surveillance of young children based on HLA genotyping.
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Th is work was funded by U01 DK63829, U01 DK63861, U01 DK63821, U01 DK63865, U01 DK63863, U01 DK63836, U01 DK63790, UC4 DK63829, UC4 DK63861, UC4 DK63821, UC4 DK63865, UC4 DK63863, UC4 DK63836, UC4 DK95300, and UC4 DK100238, and Contract No. may develop transient tTGAs that fade in titer without leading to overt CD, even in the absence of dietary alterations. Th erefore, this analysis complements those using the clinical CD phenotype and may provide information on earlier steps in the pathway leading to development of CD.
HLA-DR-DQ is the major genetic determinant of CD risk, and the paucity of published genetic associations with CDA at other loci emphasizes the central role that HLA-DR-DQ has in disease risk and development ( 18 ) . Th is paucity is even greater when considering non-DR-DQ genetic loci in the HLA region, where analyses must also be corrected for the eff ect of DR-DQ.
In a previous study, the prediction of CD was improved by 11% by adding a group of non-HLA risk variants to a model including HLA ( 19 ) . Th is suggests that additional non-HLA genes may contribute to only small changes to disease risk ( 20 ) . However, two fi ndings fi rst focused attention on the independent associations of HLA-DPB1 alleles on the DR3 background. Kagnoff et al. ( 8 ) described a signifi cantly increased frequency of both the DPB1 and DPB-3 alleles in CD patients. Th e same year, a paper by Bugawan et al. ( 11 ) described an increased frequency of DPB-3 and DPB-4.2 in CD.
In the current study, the HLA genotyping found no common alleles, in addition to DR3-DQ2, that were associated with an increased risk for CDA. Instead, the HLA allele DPB1*04:01 was associated with a 29% reduction in risk, suggesting that variants in the HLA region may infl uence the risk for CDA across all of the HLA groups included in the TEDDY study. Our results therefore support a biological interaction between DPB1*04:01 and DR3-DQ2 on the genetic susceptibility for developing CDA.
Although increases in other HLA-DPB1 alleles are compatible with a decreased frequency of DPB1*04:01 in CD patients, neither of the papers on HLA-DP associations with CD risk ( 8, 11 ) assessed the DPB1*04:01 frequency directly, perhaps owing to genotyping limitations at the time. Interestingly, the DPB1*04:01 allele has been associated with other autoimmune diseases showing both a protective eff ect for type 1 diabetes ( 21 ) and for multiple sclerosis ( 22 ) , as well as an increased risk for rheumatoid arthritis ( 23 ) , pemphigus ( 24 ) , and vasculitis ( 25 ) . To our knowledge, the association between DPB1*04:01 and CDA or CD has not been described before.
To put the magnitude of the DPB1 association in context, we compare our fi nding with the published literature for protective eff ect alleles that have been discovered through GWAS for overt CD. Our observed odds ratio for DPB1*04:01 of 0.71 is the same as the magnitude of the largest published protective fi nding for CD risk in a compilation of GWAS studies (rs13132308, MAF 0.166) ( 20 ) . In comparison, the allele frequency of HLA-DPB1*04:01 was 0.372 in the T1DGC imputation reference data set ( 26 ) and 0.421 in the TEDDY imputed data set. Although the comparison of odds ratios is between diff erent outcomes, the combination of substantial eff ect size along with relatively high allele frequency suggests that our fi nding could be as important in disease development as any of the non-HLA SNP associations found in GWAS data sets.
